Roche autoimmune disease drug disappoints in closely watched trial
An autoimmune disease drug from Roche and Chugai Pharmaceutical hit its main goal in a closely watched trial, but the...
Medicine
FDA clears first-of-its-kind Duchenne drug for broad use
Dive Brief: The Food and Drug Administration on Thursday approved a first-of-its-kind drug for Duchenne muscular dystrophy, clearing Duvyzat, a...
Medicare to cover Novo’s obesity drug for some patients
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Medicare will...
NextCure to lay off 37% of staff, dial back research plans
Cancer immunotherapy developer NextCure is laying off 37% of its staff and streamlining its research plans, the company said Thursday. ...
Mirador debuts with $400M, picking up where immune drugmaker Prometheus left off
The executives behind autoimmune drug developer Prometheus Biosciences are back, armed with more than $400 million to launch their latest...
Acelyrin eye drug heads to late-stage testing after trial win
A young biotechnology company plans to move an experimental medicine for a rare eye disease into late-stage testing after results...
Capstan heats up ‘in vivo’ cell therapy chase with $175M fundraise
Capstan Therapeutics, a biotechnology startup developing medicines that reprogram cells inside the body, has raised another $175 million to bring...
With new data, Bayer readies rival to Astellas menopause drug
Dive Brief: Bayer on Tuesday said it plans to seek regulatory approval of a drug for symptoms of menopause following...
AstraZeneca buys into radiopharmaceuticals with $2.4B deal for Fusion Pharma
AstraZeneca is the latest large pharmaceutical company to make a sizable bet on radiopharmaceutical drugs for cancer, agreeing on Tuesday...
Bluebird, short on cash, takes on $175M in debt financing
Gene therapy developer Bluebird bio has raised a large debt financing in a bid to extend its cash runway for...
Give HCPs a proactive way to reach your field team: Add inbound
Ask a healthcare professional (HCP), and chances are good that they’d like an easy way to reach out to biopharma...
J&J, Novo support Asgard’s push to make ‘in vivo’ cell therapies
Asgard Therapeutics has become the latest emerging developer of “in vivo” cell therapies to attract the attention of large drugmakers....
AstraZeneca adds another rare disease drug in $800M buyout of startup Amolyt
Dive Brief: AstraZeneca is bolstering its rare disease division with the purchase of Amolyt Pharma, an endocrine disease specialist backed...
BIO changes stance, backs bill to limit China’s role in US biotech
Dive Brief: The Biotechnology Innovation Organization on Wednesday backed legislation aiming to limit the industry’s association with Chinese life sciences...
Bristol Myers cell therapy wins first-of-its-kind approval
Dive Brief: For the first time, the Food and Drug Administration has approved a cell therapy for hard-to-treat forms of...
FDA panel backs broader use of J&J, Bristol Myers cell therapies for myeloma
Advisers to the Food and Drug Administration have endorsed the use of two cellular medicines for multiple myeloma earlier in...
Madrigal, FDA approval in hand, outlines plan to sell MASH drug
The first drug for metabolic dysfunction-associated steatohepatitis will cost $47,400 per year, its developer, Madrigal Pharmaceuticals, said Thursday. Madrigal revealed...
Madrigal wins FDA approval of first drug for MASH
The Food and Drug Administration has approved the first medicine for a common liver disease that’s been a top target...
German biotech Tubulis cashes in on ADC ‘momentum’ with €128M financing
Dive Brief: Tubulis, a German biotechnology startup developing antibody-drug conjugates, brought in €128 million, or about $140 million, to bring...
FDA to focus on ‘early deaths’ in meeting on broader CAR-T use in myeloma
Two cellular medicines for multiple myeloma were associated with an increased risk of early death in clinical testing, raising questions...
After surprise trial failure, ALS doctors brace for one less treatment option
For Rick Bedlack, director of the ALS clinic at Duke University, tough times come with the job. He and his...
Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease
Allogene Therapeutics is turning to gene editing startup Arbor Biotechnologies for help developing “off-the-shelf” cell therapies for autoimmune diseases, the...
Boehringer, Sosei Heptares team up in schizophrenia drug deal
Boehringer Ingelheim has formed a partnership with Sosei Heptares in a deal aimed at developing a new type of schizophrenia...
Roche, following setbacks, turns to its next Alzheimer’s drug
Dive Brief: Roche’s experimental Alzheimer’s disease drug trontinemab showed “best-in-class” potential based on its ability to quickly clear clumps of...
J&J’s growing rare disease focus brings a potential multi-use treatment to the table
Rare diseases, once a miniscule chapter in the pharma playbook, have become a major focus for even the biggest companies...
Biden proposes strengthening Medicare’s drug pricing power
Dive Brief: President Biden is taking on a bipartisan bogeyman ahead of a critical State of the Union speech, targeting...
Novo’s latest obesity pill spurs major weight loss in small trial
Dive Brief: An experimental pill developed by Novo Nordisk helped obese people lose 13% of their body weight after three...
Why Cigna is capping cost increases for pricey obesity drugs
Cigna is moving to limit how much health insurance providers and employers have to pay for pricey and in-demand obesity...
FDA delays decision on Lilly’s closely watched Alzheimer’s drug
Dive Brief: The Food and Drug Administration is delaying an approval decision on Eli Lilly’s experimental medicine for Alzheimer’s disease...
FDA clears use of Novo’s obesity drug to protect heart health
The Food and Drug Administration has expanded the label for Novo Nordisk’s fast-selling weight loss drug Wegovy following study results...
Amylyx ALS drug fails crucial study, putting company’s future in doubt
A large clinical trial meant to confirm the benefits of a new ALS medication has instead failed, dealing a major...
NodThera says inflammation drug has positive effect in Parkinson’s
A Boston-based biotechnology company on Thursday said its most advanced drug showed positive effects in a clinical trial of Parkinson’s...
Alumis, taking aim at Bristol Myers, pulls in $259M for TYK2 drug work
Dive Brief: Biotechnology startup Alumis on Wednesday raised $259 million in Series C funding to advance a portfolio of oral...
European VC Invivo readies its latest fund to back new biotechs
Dive Brief: Barcelona-based venture capital firm Invivo Partners is preparing to close an expected fund of 100 million euros, or...
Sionna raises another $182M to challenge Vertex in cystic fibrosis
Dive Brief: Sionna Therapeutics, a Waltham, Massachusetts biotechnology startup, announced Wednesday it raised a $182 million Series C round to...
Alnylam, Roche blood pressure drug scores in second mid-stage trial
Dive Brief: An experimental RNA-based medicine developed by Alnylam Pharmaceuticals, when added to standard drugs, helped lower blood pressure significantly...
Biotech IPOs heated up to start 2024. Will the surge last?
After more than two years in the doldrums, initial public offerings, an important indicator of the biotechnology industry’s health, have...
Nocion, chasing GSK, pulls in $62M for chronic cough drug
Investors have poured $62 million into a biotechnology startup developing a drug to treat chronic cough. Nocion Therapeutics, headquartered in...
Q&A: How AI and ML are reshaping the research landscape
In a rapidly evolving landscape where artificial intelligence (AI) and machine learning (ML) have become household terms, their impact on...
Abingworth invests in Trodelvy development in deal with Gilead
Dive Brief: Abingworth, a venture capital group owned by Carlyle, will invest as much as $210 million to help Gilead...
Gritstone to lay off 40% of workforce after costly study delay
Gritstone Bio will lay off about 40% of its workforce after missing out on funding it expected to receive this...
CDC panel mulls changes to RSV vaccine recommendation
Advisers to the Centers for Disease Control and Prevention are weighing updates to their recommendation older adults get vaccinated for...
FogPharma pulls in $145M to support cancer drug research
Dive Brief: Cancer drug developer FogPharma has raised $145 million in fresh funding, the company revealed Friday, announcing a Series...
Pfizer, looking for a jumpstart, leans into cancer drug research
Pfizer believes the answer to its sliding valuation lies in oncology. The company, which is coming off one of the...
With BlossomHill, former Turning Point execs take aim at cancer, autoimmune disease
A good track record can be valuable in the uncertain and risky world of drug development. For a group of...
Cure Ventures backs a cell therapy startup targeting Parkinson’s
Kenai Therapeutics, a San Diego-based biotechnology company, has raised $82 million to support its work developing cell therapies for nervous...
Women’s health company Obseva to wind down, lay off staff
Dive Brief: ObsEva, a women’s health drug developer, on Wednesday said it plans to wind down its business and let...
Incannex says psilocybin therapy lowered anxiety in small study
An Australian-based biotechnology company says a mid-stage clinical trial has shown that psilocybin, a psychedelic compound found in many mushroom...
Janux shares triple on early cancer immunotherapy data
Dive Brief: Shares in Janux Therapeutics tripled in value Tuesday on early clinical trial results that analysts viewed as a...
Viking data suggest obesity drug could rival Zepbound, Wegovy
Dive Brief: An experimental weight loss drug developed by Viking Therapeutics helped overweight and obese people lose up to 15%...
GSK drug meets goal in late-stage gonorrhea study
Dive Brief: GSK said Monday that its oral antibiotic succeeded in a late-stage trial in gonorrhea, proving to be as effective...
Humira biosimilar from Alvotech, Teva wins FDA approval on third attempt
Dive Brief: The Food and Drug Administration on Saturday approved Alvotech and Teva Pharmaceuticals’ Simlandi, a biosimilar of the most...
Choosing laboratory equipment with workplace experience in mind
The creativity and expertise of the researchers, technicians and assistants working in healthcare and biopharmaceutical laboratories are critical for every...
ORI Capital, the venture firm behind CG’s big IPO, raises new biotech fund
ORI Capital, the China- and U.S.-based venture investor behind the biotechnology sector’s largest initial public offering this year, has raised...
Novavax agrees to pay Gavi in settlement over COVID vaccine contract
Dive Brief: Novavax will pay as much as $475 million to settle a dispute with Gavi, the Vaccine Alliance over...
Moderna pitches RSV shot, new vaccines after ‘difficult year of transition’
Dive Brief: Moderna shares rose by as much as 10% Thursday morning after the COVID-19 vaccine developer reported fourth quarter...
BioMarin preaches patience amid slow sales for hemophilia gene therapy
Dive Brief: BioMarin Pharmaceutical is struggling to sell the first marketed gene therapy for the most common form of hemophilia,...
J&J secures EMA backing for earlier CAR-T use in multiple myeloma
Dive Brief: The European Medicine Agency’s main drug review committee on Friday supported expanding the approval of Johnson & Johnson...
Biden administration pledges $100M toward women’s health research
The Biden Administration, through the Advanced Research Projects Agency for Health, has committed to invest $100 million into women’s health...
Frontier gets $80M, Galapagos’ backing to make a better KRAS drug
Biotechnology startup Frontier Medicines has pulled in $80 million in new funding to support a targeted cancer drug the company...
Vir, in midst of restructuring, loses its chief medical officer
Infectious disease drug developer Vir Biotechnology on Tuesday disclosed that chief medical officer Phil Pang is stepping down from his...
NEJM paper fills in details on ‘remarkable’ CAR-T result in autoimmune disease
A new research paper offers the most thorough look yet at a study that sparked the drug industry’s recent experimentation...
AstraZeneca gets new Tagrisso OK as drug succeeds in another trial
Dive Brief: AstraZeneca’s targeted cancer therapy Tagrisso can now be used alongside chemotherapy to treat a common type of locally...
FDA puts hold on Rapt trials of drug for eczema, asthma
Dive Brief: Shares of Rapt Therapeutics fell sharply Tuesday after the company disclosed U.S. regulators ordered a halt of two...
Translating complex data into actionable insights, to create big value for smaller biotech companies
Lisa Benincosa is senior vice president of clinical pharmacology strategy at the specialized Clinical Research Organization (CRO), Allucent. Here she...
Versant-backed Firefly Bio wants to make the next generation of ADCs
Dive Brief: Firefly Bio, a startup working to develop a new kind of cancer medicine, announced Thursday it had raised...
Aurinia to cut research after sale process fails to find a buyer
Dive Brief: Aurinia Pharmaceuticals will restructure its operations and give money back to shareholders after failing to find a buyer...
Astellas teams up with startup Kelonia to make ‘in vivo’ cell therapies
Astellas Pharma is delving deeper into cell therapies for cancer, announcing Thursday a research deal to develop a pair of...
Gilead reviewing drug acquired in $5B buyout after latest setback
Gilead Sciences is evaluating the future of a cancer drug acquired in a multibillion-dollar deal following a new setback the...
FDA to review expanded use of Sarepta Duchenne gene therapy
Dive Brief: The Food and Drug Administration will decide by June 21 whether to loosen the restrictions surrounding use of...
ALS drug from Denali, Sanofi falls short in mid-stage study
Dive Brief: An experimental drug being developed by Denali Therapeutics and partner Sanofi for ALS failed to meet its goal...
Intellia, ReCode partner on genetic medicines for cystic fibrosis
Intellia Therapeutics will work with a private biotechnology company to develop genetic medicines for cystic fibrosis, with an initial focus...
Alnylam changes to heart drug trial spark doubts, sinking shares
Dive Brief: Alnylam Pharmaceuticals is delaying the readout of a closely watched Phase 3 trial in the heart disease transthyretin...
Ipsen drug approved by FDA for early pancreatic cancer
Dive Brief: The Food and Drug Administration has approved a new regimen for pancreatic cancer, clearing Ipsen’s Onivyde to be...
Sage offers details on launch of new postpartum depression pill
Sage Therapeutics said its new medicine, the first oral treatment for postpartum depression, is off to an encouraging start, with...
Biogen has a fuzzy line of sight on prized Alzheimer’s drug
One of the world’s largest biotechnology companies wants a new calling card. Long known for multiple sclerosis drugs, Biogen believes...
BioAge raises $170M to back Phase 2-ready obesity drug
Dive Brief: Biotechnology startup BioAge Labs has raised $170 million to support an experimental pill it plans to test alongside...
CSL heart drug misses goal in large study
An experimental plasma-based infusion developed by CSL failed to keep people at high cardiovascular risk from having heart attacks, strokes...
Alys launches with $100M and a pipeline of skin disease drugs
Six biotechnology startups are merging into a new skin drug developer called Alys Pharmaceuticals, which launched on Monday with $100...
Chart a course for sustainable growth
As life sciences and pharma services companies forge ahead in 2024, they find themselves at a critical juncture―realizing unparalleled opportunities...
Obesity drug mania takes over Amgen’s earnings call
Amgen is a global pharmaceutical company worth more than $160 billion. Nine of its marketed medicines are blockbuster products by...
BioNTech partners with Autolus to boost cell therapy manufacturing
BioNTech will pay $50 million and make a $200 million investment in Autolus Therapeutics as the company most famous for...
Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts
The CEOs of three major drugmakers defended the prices they charge U.S. patients in a Senate committee hearing Thursday, claiming...
Kyverna CEO Peter Maag on courting investors in a ‘volatile’ IPO market
Biotechnology initial public offerings are showing sustained signs of life for the first time in two years, and Kyverna Therapeutics’...
Takeda speeds narcolepsy drug to late-stage testing
Takeda Pharmaceutical plans to quickly begin late-stage testing of an experimental drug for narcolepsy, which, if successful, could help the...
Gene editing biotech Metagenomi pulls off nearly $94M IPO
Dive Brief: Metagenomi, a gene editing startup spun out of research at the University of California, Berkeley, brought in about...
Neurona raises another $120M for brain disease cell therapies
Dive Brief: Neurona Therapeutics, a San Francisco-based biotechnology company, has raised another $120 million to fuel its research into cell...
Kyverna IPO adds to biotech momentum with $319M fundraise
Dive Brief: Kyverna Therapeutics raised $319 million in a larger-than-expected initial public offering Thursday, adding to an early, but notable,...
BridgeBio sells partial rights to dwarfism drug for $100M
Dive Brief: BridgeBio Pharma is selling partial rights to an experimental drug for a common form of dwarfism to Japanese...
Eisai falls behind on Leqembi patient goal
The Japan-based pharmaceutical firm Eisai had hoped that, by the end of March, 10,000 patients in the U.S. would be...
Lilly sales surge on obesity, diabetes drug demand
Sales of Eli Lilly’s diabetes drug Mounjaro exceeded $5 billion in 2023, its first full year on the market, the...
J&J says top drug prospect works across autoimmune disorders
On Monday, Johnson & Johnson said one of its most closely watched experimental medicines appears to have positive effects on...
Novo Holdings to buy contract drugmaker Catalent for $16.5B
Novo Holdings, the controlling shareholder of Danish drugmaker Novo Nordisk, will buy contract manufacturer Catalent for $16.5 billion in a...
Biogen quits Aduhelm, handing back rights to original developer
In 2021, the Food and Drug Administration for the first time approved a medicine meant to slow the progression of...
Avrobio’s road ends in reverse merger with Tim Springer-backed startup
Dive Brief: The gene therapy company Avrobio agreed to a reverse merger with startup Tectonic Therapeutic after years of struggling...
Roche shuffles early stage pipeline as it joins obesity rush
Roche is reshaping its early-stage pipeline of experimental drugs, jettisoning eight drug candidates in neurological conditions and oncology as it...
Takeda pays $300M to license Protagonist drug for blood disorder
Dive Brief: Protagonist Therapeutics, a biotechnology company focused on peptide drugs, is teaming up with Takeda Pharmaceutical on an experimental,...
Arch, a prolific biotech creator, is raising $3B for startup investing
Arch Venture Partners, one of the biotechnology sector’s most prolific company creators, is raising a new $3 billion fund, according...
Brain drug developer Alto Neuroscience prices $129M IPO
Another biotechnology company has hit Wall Street via an initial public offering, the third to do so this year in...
Merck keeps deal focus with Keytruda patent cliff on horizon
Merck & Co. plans to continue seeking out multibillion-dollar biotechnology deals to supplement its own drug research as it prepares...
Sanofi appoints Nestlé executive as new finance chief
Nestlé veteran François-Xavier Roger will succeed Sanofi chief financial officer Jean-Baptiste Chasseloup de Chatillon on April 1, the French pharmaceutical...
New CMS pilot to test payment scheme for pricey sickle cell gene therapies
The U.S. government will test whether centrally coordinating insurance coverage can help people with sickle cell disease access expensive new...
GSK sales of RSV vaccine stay strong, beating forecast
GSK on Wednesday reported higher-than-expected sales of its RSV vaccine Arexvy, providing further evidence of the product’s strong uptake. The...
Cour gets $105M, pharma help to ‘reprogram’ autoimmune disease
Dive Brief: Biotechnology startup Cour Pharmaceuticals has raised $105 million to advance a portfolio of medicines for autoimmune diseases. The...
Gilead deepens investment in Arcus and TIGIT drugs
Dive Brief: Gilead has bought a bigger stake in cancer drug developer Arcus Biosciences, announcing Monday it will spend $320...
CAR-T for lupus: the ‘tip of the iceberg’ for cell therapy in autoimmune disease
The clue came, as they often do, from an unexpected source. Some sixteen months ago, a small study of five...
J&J focuses on newer meds to offset Stelara patent cliff
Johnson & Johnson CEO Joaquin Duato sold 2023 as a “remarkable year” on an earnings call with investors Tuesday. But...
Novo strikes another obesity drug deal
Dive Brief: Novo Nordisk is adding yet another prospect to its obesity drug pipeline, this time from a biotech company...
BenevolentAI appoints former Bayer R&D chief as CEO
After a rocky year that featured a restructuring, job cuts and the resignation of its CFO, BenevolentAI is looking to...
RayzeBio drew other pharma interest before Bristol Myers deal
Radiopharmaceutical drugmaker RayzeBio drew interest from two other large drugmakers before agreeing to a $4.1 billion buyout by Bristol Myers...
PTC Duchenne drug approval set to be revoked in Europe
European authorities are set to rescind the approval of a Duchenne muscular dystrophy drug that’s been on the market there...
EMA recommends earlier use of Bristol Myers cell therapy for multiple myeloma
Dive Brief: Bristol Myers Squibb’s cell therapy for multiple myeloma, Abecma, should be approved for use in patients whose disease...
Cancer drugmaker ArriVent follows on CG’s heels with $175M IPO
Dive Brief: ArriVent Biopharma is the second biotechnology company to go public this year, raising $175 million in an initial...
At FDA meeting, experts wrestle with hurdles to developing preterm birth drugs
The Food and Drug Administration this week convened a group of experts to discuss ways to develop new drugs for...
CG Oncology prices larger-than-expected $380M IPO in hopeful sign for biotech
Cancer drug developer CG Oncology has raised $380 million in an initial public offering than was larger than it expected, a...
Lilly gene therapy finding puts focus on hearing loss treatment pipeline
An 11-year-old boy who was born deaf can hear after receiving an experimental gene therapy, developer Eli Lilly reported on...
Sanofi to buy Inhibrx in deal worth up to $2.2B
Sanofi on Tuesday said it will acquire San Diego biotechnology company Inhibrx in a complex deal that could be worth...
FDA orders new cancer warnings for CAR-T therapies
Dive Brief: The makers of CAR-T cell therapies will need to warn about the risk of new blood cancer, the...
Coherus sells Lucentis biosimilar to Sandoz for $170M
Dive Brief: Coherus Biosciences on Monday said it has agreed to sell its approved biosimilar Cimerli, along with supporting staff,...
Gilead ADC medicine misses goal in closely watched lung cancer study
Dive Brief: Gilead Sciences on Monday said its cancer drug Trodelvy missed the main goal of a Phase 3 trial...
Bayer signals ‘significant’ layoffs in plan to shrink bureaucracy
As part of a makeover promised last year, Bayer is beginning a process of staff reductions that aims to slice...
BridgeBio strikes drug royalty deal for cash infusion
BridgeBio Pharma has agreed to sell future royalties on an experimental rare disease drug in exchange for $500 million if...
Five years after Shire deal, Takeda hopes to reap rewards of latest reinvention
Five years ago this month, Takeda Pharmaceuticals completed a $62 billion acquisition of Shire — one of the largest deals...
Ikena Oncology to lay off 35% of staff
Biotechnology company Ikena Oncology on Thursday said it would lay off staff and reallocate resources toward two experimental cancer drugs....
Sanders threatens to subpoena J&J, Merck CEOs over drug prices
A Congressional committee may subpoena the CEOs of Johnson & Johnson and Merck & Co. to testify about the differences...
Novartis details first-line data for radiopharma drug Lutathera
A radiopharmaceutical drug from Novartis kept a rare type of neuroendocrine cancer at bay for longer than did standard therapy,...
Gene therapy biotech Jaguar spins out manufacturing company
Jaguar Gene Therapy is spinning out part of its business to handle the specialized work of manufacturing cell and gene...
A South Korean investment firm starts first US biotech fund
Mirae Asset Capital Life Science, a new venture capital fund, launched on Thursday, joining several other new firms that have...
Kyverna sets plans for IPO in test of biotech enthusiasm
Dive Brief: Kyverna Therapeutics on Tuesday revealed plans to go public, testing the waters in a biotechnology market that hasn’t...
Comanche Biopharma raises $75M to fund preeclampsia drug testing
Dive Brief: Massachusetts-based startup Comanche BioPharma has raised $75 million in new venture funding to advance an experimental treatment targeting...
FDA widens approval of Vertex’s CRISPR medicine to treat beta thalassemia
The Food and Drug Administration on Tuesday approved Vertex Pharmaceuticals’ CRISPR-based medicine Casgevy for the inherited blood condition beta thalassemia, expanding...
The biopharma industry outlook on 2024: Guarded optimism for a rebound
Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year brought a stock market...
Newly optimistic, biotech investors weigh lessons of sector’s downturn
The J.P. Morgan Healthcare Conference, a yearly temperature taker for the biotechnology industry, had a different feel in 2024. For...
EU regulators to consult advisers in review of Eisai Alzheimer’s drug
European regulators will seek outside advice before making a decision on approval of Eisai and Biogen’s Leqembi medicine for Alzheimer’s...
FDA says no ‘clear relationship’ between GLP-1 drugs and suicide risk
Dive Brief: The use of GLP-1-based drugs to treat obesity and diabetes has no “clear relationship” with the risk of...
Backed by billionaires, a new biomedical institute tests an unorthodox approach
A group of high-profile scientists and billionaire financiers are building a new biomedical research institute that they claim will offer...
Recursion’s Chris Gibson on AI in biotech, competition and ‘virtuous cycles’
Chris Gibson, the CEO of Recursion Pharmaceuticals, thinks the future of drug discovery lies within a ChatGPT-like interface. At a...
Venture funding, dealmaking slowed in biotech last year: Pitchbook
Dive Brief: The number and amount of biotechnology financings dipped in 2023, with venture firms investing 25% fewer dollars in...
JPM24: Novartis’ head start, FTC fallout and Bluebird’s price defense
The mood shifts on the third day of the J.P. Morgan Healthcare Conference. Deals have been announced and news peters...
5 questions facing pharma in 2024
The arrival of powerful new drugs for obesity has reshaped the pharmaceutical industry, transforming Eli Lilly and Novo Nordisk into...
GSK to buy asthma drug startup Aiolos for $1B
Over the span of five months, biotechnology startup Aiolos Bio launched, raised initial funding from venture investors and negotiated a...
JPM24: Pfizer’s tough sell, the next Karuna and building a biotech platform
Biotechnology’s embrace of artificial intelligence was never more literal than Tuesday at the J.P. Morgan Healthcare Conference, when AI drug...
FDA authorizes Florida to import drugs from Canada
For the first time, the Food and Drug Administration has authorized a U.S. state to import prescription drugs from Canada,...
An unusual drugmaker raises north of $100M for ecstasy-based PTSD therapy
A California-based company has raised tens of millions of dollars to support its mission of bringing an ecstasy-based therapy to...
Intellia to lay off staff, cut some early research
CRISPR specialist Intellia Therapeutics on Thursday said it will lay off about 15% of its workforce as it pauses some...
Lilly launches online service for home delivery of weight loss drug
Dive Brief: Eli Lilly wants to make it easier for people to access its medicines for obesity, diabetes and migraine,...
Pfizer wins Canadian OK for hemophilia treatment, its first gene therapy
Dive Brief: Canada’s health regulators have approved Pfizer’s gene therapy for hemophilia B, the company said Wednesday, making it the...
FDA ends busy year with three drug rejections
The Food and Drug Administration closed out 2023 with rejections of three drugmaker applications for first approval or expanded use,...
Novartis deepens ties with Voyager via $100M gene therapy deal
Dive Brief: Swiss pharmaceutical company Novartis has formed a new collaboration with partner Voyager Therapeutics, agreeing Tuesday to license one...
10 clinical trials to watch in the first half of 2024
A non-addictive pain pill faces its definitive test, while study results in ALS, a rare heart disease and lung cancer...
As ALS research booms, one treatment center finds itself in the spotlight
Merit Cudkowicz has spent her career treating some of the most unforgiving illnesses. She’s watched Alzheimer’s disease steal memories and...
Sanofi scraps a top ADC prospect after study setback
Dive Brief: Sanofi will stop developing one of its top cancer drug prospects after the experimental treatment fell short in...
BioMarin strikes deal with Elliott, agrees to review business
Dive Brief: Weeks after installing a new CEO, BioMarin Pharmaceutical is overhauling oversight of the company at the board level....
Ionis, Astrazeneca win FDA approval of competitor to Alnylam drug
Dive Brief: The Food and Drug Administration on Thursday approved a new medicine for a form of the rare disease...
Bristol Myers to acquire brain drug developer Karuna for $14B
Bristol Myers Squibb has agreed to acquire Karuna Therapeutics for $14 billion, betting that the biotechnology company’s experimental schizophrenia drug...
Sarepta tests FDA flexibility with bid to expand Duchenne gene therapy’s approval
Sarepta Therapeutics has asked the Food and Drug Administration to expand approval of its gene therapy for Duchenne muscular dystrophy,...
J&J bets bigger on MeiraGTx’s eye gene therapy
Dive Brief: Gene therapy developer MeiraGTx is selling its remaining financial interest in an eye-disease treatment partnered with Johnson &...
Clene says its ALS drug data is not yet enough for FDA
Dive Brief: Clene Nanomedicine on Thursday said the Food and Drug Administration doesn’t believe the company has gathered enough evidence...
Argenx autoimmune drug study fails in blow to expansion hopes
Dive Brief: Argenx lost a quarter of its value Wednesday after reporting the second research setback in two months for...
GSK adds to ADC dealmaking with second Chinese biotech pact
Dive Brief: GSK is deepening its investment in cancer treatments called antibody-drug conjugates, announcing Wednesday plans to pay $185 million...
Biogen holds onto Tecfidera market in Europe for a little longer
Dive Brief: The European Commission has revoked the approvals for five generic versions of Biogen’s multiple sclerosis medicine Tecfidera, ensuring...
Investors still aren’t sold on UniQure’s gene therapy for Huntington’s
Dive Brief: Shares of UniQure dipped more than 10% Tuesday morning after the biotechnology company released more data from a...
Foundation behind Novo Nordisk to invest $260M in vaccine R&D
Dive Brief: The Novo Nordisk Foundation, which owns a controlling stake in drugmaker Novo Nordisk, said Monday it will invest...
Point radiopharma drug results disappoint in prostate cancer study
Dive Brief: A targeted radiation drug being developed by Indianapolis-based Point BioPharma met its goal in a late-stage prostate cancer...
Vir to lay off staff, cut costs amid setbacks building on COVID success
Dive Brief: Vir Biotechnology on Thursday announced a restructuring that will result in a 12% reduction in its workforce as...
Amgen finds a new top scientist in Novartis veteran Bradner
Amgen has a new top scientist, announcing Thursday the appointment of Novartis veteran and prolific biotechnology startup founder Jay Bradner...
European regulators push Biogen, CRISPR drugs toward approval
The committee that recommends whether drugs should be approved in Europe has thrown its support behind the first medicine based...
FDA widens use of cancer drug Merck acquired for $1B
Dive Brief: The Food and Drug Administration on Thursday broadened use of a drug Merck & Co. acquired in a...
